Form 4: Director Li Nan Reports Odyssey Therapeutics IPO Activity

Director Li Nan disclosed the conversion of preferred stock and participation in the Odyssey Therapeutics IPO.

Summary

• Director Li Nan reported the conversion of 16,611,626 shares of Series D Convertible Preferred Stock into 1,709,543 shares of Common Stock.
• The conversion occurred at a 1-for-9.7170 ratio in connection with the company's initial public offering.
• The reporting person acquired an additional 1,111,111 shares of Common Stock at $18.00 per share in the IPO.
• Total beneficial ownership following these transactions is 3,333,516 shares held indirectly through Dimension Capital II, L.P.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral-to-positive disclosure, as it confirms insider commitment to the company's IPO valuation.

Positives

• Director demonstrated confidence in the company by purchasing 1,111,111 shares at the IPO price of $18.00.
• Successful conversion of Series D Preferred Stock indicates progress toward the company's public listing.

Negatives

• None identified in this filing.

Risks

• The reporting person disclaims beneficial ownership of the securities except to the extent of his indirect pecuniary interest, highlighting complex ownership structures.

Future Outlook

The filing does not provide forward-looking guidance, as it is a disclosure of past transactions related to the IPO.

Industry Context

StockSavvy.ai notes that insider participation in an IPO at the offering price is generally viewed as a positive signal of management and board alignment with public shareholders.

Comparison to Industry Standards

• Insider participation in IPOs is a standard practice for biotech firms to signal confidence to institutional investors.
• The conversion of preferred stock to common stock is a standard procedural step for venture-backed companies transitioning to public markets.

Related Party Transactions

• Securities are held by Dimension Capital II, L.P., which is controlled by entities associated with the reporting person.

Stakeholder Impact

• Shareholders may view the director's purchase of IPO shares as a sign of long-term commitment to the company's success.

Next Steps

• Ongoing compliance with Section 16 reporting requirements for future transactions.

Key Dates

Keywords

Odyssey Therapeutics, ODTX, Form 4, Insider Trading, IPO, Director, Equity Conversion